濮阳东方妇科价格偏低(濮阳东方医院治早泄技术可靠) (今日更新中)

MOSCOW, Sept. 21 (Xinhua) -- A Russian Proton-M carrier rocket carrying a military spacecraft blasted off early Wednesday from the Baikonur space center in Kazakhstan, the first launch since a series setbacks of Russian rocket launch in August.Colonel Alexei Zolotukhin, spokesman of the Russian Space Forces, told reporters that the successful launch took place at 02:47 Moscow time (2247 GMT Tuesday) as scheduled."The spacecraft is scheduled to separate from the Briz-M booster at 11:48 Moscow time (0748 GMT)," Zolotukhin said.The military spacecraft delivered by the Proton-M belongs to the Russian Defense Ministry.Local reports said the Wednesday launch was originally planned for Aug. 31, but was postponed due to an investigation into a failed launch of a Proton-M rocket carrying an Express-AM4 satellite on Aug. 18.After the failure, Russia decided to suspend launches of rocket Proton-M pending the outcome of a probe into the accident.On Aug. 24, a Progress M-12M cargo ship also failed to reach the orbit due to a rocket malfunction. Russia delayed the launch of next manned spaceship to the International Space Station (ISS).

WELLINGTON, June 7 (Xinhua) -- Scientists in New Zealand have developed a new drug to fight previously untreatable hypoxic cancer tumors, which form in areas of the body starved of oxygen.The researchers at the Auckland University have entered an agreement for the clinical development of CEN-209, which was developed over 10 years of research, said a statement from the university Tuesday.CEN-209 was designed to enhance the effectiveness of radiotherapy and chemotherapy in solid hypoxic tumors, which were resistant to standard cancer therapies, said the statement. In lung cancer patients for example, about half of tumors had hypoxic regions.The new drug worked by damaging the DNA of hypoxic cancer cells, while leaving normal, healthy tissues alone.CEN-209 was designed and created by researchers at the university's Auckland Cancer Society Research Centre (ACSRC), using computer models of drug transport within tumors to accurately predict the anti-tumor activity of the drugs."Our computer models of drug transport developed in-house allowed the synthetic chemists to test their design theories and considerably shortened the discovery process," said Associate Professor Michael Hay, who led the ACSRC research chemists."CEN-209 improves markedly on previous agents in this class in terms of its ability to penetrate tumors, and this is reflected by its improved activity in the laboratory, when combined with long or short courses of radiotherapy," said researcher Professor Bill Wilson.Under the agreement between the university's Auckland UniServices Ltd. and California-based Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc., Centella will have exclusive rights to CEN-209, which it will develop and trial with Cancer Research UK.The work on CEN-209 is the culmination of a program initiated with funding from the U.S. National Cancer Institute, and more recently from the Maurice Wilkins Centre for Biodiscovery. Ongoing preclinical research on CEN-209 and a backup compound was funded by grants from the Auckland Medical Research Foundation, Genesis Oncology Trust and Health Research Council of New Zealand, said the statement.

OTTAWA, Sept. 29 (Xinhua) -- Climate change could cost Canada billions of dollars a year by the end of this decade, a government funded study group announced Thursday.The National Round Table on the Environment and the Economy said the cost of climate change for Canada could start at roughly 5 billion Canadian dollars per year in 2020 and increase to between 21 billion and 43 billion per year by 2050. Those costs would come from shoreline damage, public health problems, and disruptions to the economy.It also predicted a slight increase in deaths in major cities from heat and air pollution.The round table researchers estimated the cost of climate change is expected to be roughly 0.8 percent to 1.0 percent of GDP -- or 43 billion Canadian dollars a year -- by 2050, if the problem is allowed to worsen.But the report did not address possible benefits, such as reduced demand for hea

WASHINGTON, July 18 (Xinhua) -- Exposure to secondhand smoke ( SHS) is associated with increased risk of hearing loss among adolescents, according to a report in the July issue of Archives of Otolaryngology -- Head and Neck Surgery.Among U.S. children, approximately 60 percent are exposed to SHS, according to background information in the article. Studies have associated exposure to secondhand smoke prenatally or during childhood with various health conditions, from low birth weight and respiratory infections to behavioral problems and otitis media. Children exposed to SHS are more likely to develop recurrent otitis media, the authors note. "Secondhand smoke may also have the potential to have an impact on auditory development, leading to sensorineural hearing loss (SNHL)," they add.Anil Lalwani and colleagues from New York University Langone Medical Center examined the risk factors for SNHL, including SHS, among adolescents, stratified by demographic groups. They included 1,533 individuals from 12 years to 19 years of age who participated in the National Health and Nutrition Examination Survey from 2005 to 2006.Participants were interviewed about their health status and family medical history, exposure to SHS, and self-recognition of hearing impairment. In addition, they underwent a physical examination, including blood testing for cotinine (a by-product of nicotine exposure), and hearing tests.Compared with teens who had no SHS exposure, those who were exposed to secondhand smoke exhibited higher rates of low- and high-frequency hearing loss. The rate of hearing loss appeared to be cumulative, increasing with the level of cotinine detected by blood tests. The results also demonstrated that more than 80 percent of participants with hearing loss did not realize they had impairment.As hearing loss early in life can cause problems with development and functioning, the authors suggest that these results have "significant implications for public health in the United States."They note that most adolescents do not receive screening for hearing loss in the absence of risk factors.If further studies replicate these results, they state, SHS could be considered one such risk factor.

LOS ANGELES, July 28 (Xinhua) -- Mainly due to rampant obesity, Americans' life expectancy is one-and-a-half-year shorter than that of Western Europeans on the average, according to a new study published on Thursday.But 40 years ago, Americans could expect to live slightly longer than Europeans, said the study jointly conducted by researchers from University of Southern California (USC), the Harvard School of Public Health and the RAND Corp., a non-profit think tank.In addition to Western Europeans, Americans also die younger than the residents of most other developed nations, according to the study appearing in the July issue of Social Science & Medicine.The life-expectancy disparity, which begins around the age of 50, stems from higher levels of middle-age obesity and obesity-related chronic diseases, such as hypertension and diabetes, said the study.In the first half of the last century, average life expectancy increased by saving more babies, said author Dana Goldman, director of the Schaeffer Center for Health Policy and Economics at the USC."But now it is reduction in mortality among the elderly, rather than the young, that propels increases in life expectancy," he said. "The question is whether 'being American' is an independent mortality risk factor."If 50-year-old U.S. adults could be as healthy as Europeans, it could save Medicare and Medicaid 632 billion dollars by 2050, the study said.Though the transition to better health initially raises expenditures, the researchers estimate that by 2050 healthcare savings from health improvements among the middle age could total more than 1.1 trillion dollars."The international life expectancy gap appears much easier to explain than gaps within countries: there is no American-specific effect on longevity beyond differences in disease at age 50," said Darius Lakdawalla, an associate professor in the USC School of Policy, Planning and Development.

来源：资阳报